EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents

Rochelle Woodland iD, Adi Suwandi iD, Awgichew Behaile Teklemariam iD, Nidhish Francis iD, Li Li iD, Kenneth A Chinkwo iD, Jonathan B Baell iD, David J Leaver iD

ChemMedChem · 28.10.2026 · 21 (20)

DOI: 10.1002/cmdc.70534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 22.10.2026. Verfasst von Rochelle Woodland und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Enzyme Inhibitors, Histone Acetyltransferases. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of lysine acetyltransferase (KAT) inhibitors as anticancer agents has progressed rapidly from initial tool compounds to numerous molecules entering clinical trials. The most clinically advanced KAT6A inhibitor, prifetrastat (PF‐07248144), entered Phase III clinical trials in 2025. The discovery of prifetrastat is an excellent example of instrumental contributions made by Australian biomedical and medicinal chemistry researchers to the creation of innovative and cutting‐edge anticancer therapeutics. Within this perspective we summarize KAT6A structural biology and structure–activity relationships (SAR) for acylsulfonylhydrazides, [1,2,4]thiadiazines and benzisoxazole sulfonamide inhibitors in addition to providing updates on KAT6A inhibitors that have already entered into clinical trials. Key clinical challenges and opportunities facing the field are discussed herein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsEnzyme InhibitorsHistone AcetyltransferasesHumansMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

clinical triallysine acetyltransferasesstructural biology

Substanzen

Antineoplastic AgentsEnzyme InhibitorsHistone AcetyltransferasesKAT6A protein, human

Autor:innen und Institutionen

  • School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Gulbali Institute, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • Manas AI, New York, New York, USA.
  • Department of Chemistry and Biochemistry, Lubbock Christian University, Lubbock, Texas, USA.

ORCID-Profile: Rochelle Woodland, Adi Suwandi, Awgichew Behaile Teklemariam, Nidhish Francis, Li Li, Kenneth A Chinkwo, Jonathan B Baell, David J Leaver

Förderung

  • The National Health and Medical Research Council of Australia

Zitieren

APA

Woodland, R., Suwandi, A., Teklemariam, A. B., Francis, N., Li, L., Chinkwo, K. A., Baell, J. B., & Leaver, D. J. (2026). A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70534

Vancouver

Woodland R, Suwandi A, Teklemariam AB, Francis N, Li L, Chinkwo KA, et al. A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70534

BibTeX
@article{Woodland2026,
  author = {Woodland, Rochelle and Suwandi, Adi and Teklemariam, Awgichew Behaile and Francis, Nidhish and Li, Li and Chinkwo, Kenneth A and Baell, Jonathan B and Leaver, David J},
  title = {A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {20},
  doi = {10.1002/cmdc.70534}
}
Kostenlos starten →